Target delivery of remdesivir may minimize the hepatotoxicity in COVID-19

( An International Open Access , Peer-reviewed, Refereed Journal )

IJIRTEXPLORE- Search Thousands of research papers

ISSN: 2349-6002 ESTD Year: 2014

UGC approved journal no 47859

Target delivery of remdesivir may minimize the hepatotoxicity in COVID-19
Author(s):
Dr. Keerthi G S Nair, Dr. P Manoj Kumar
Keywords:
COVID-19; Hepatotoxicity; Remdesivir; Nanoparticle; Target delivery; Improved clinical outcome
Abstract
Remdesivir is a broad-spectrum antiviral agent meant to inhibit viral RNA polymerases against members of several virus families, including filoviruses. Although reported for significant clinical improvements in COVID-19, a detailed observation of the connection with the drawbacks of remdesivir therapy was poor pulmonary distribution and hepatotoxicity (transaminase elevation) was recorded that resulted in discontinuation of remdesivir therapy. Nanodrug delivery facilitates a large drug payload to the targeted site improving the efficacy. With the lesser dose administered, could be expected for minimized adverse events. Additional payload of ashwagandha will protect the liver from the damages caused if any. Remdesivir may be a safe and an effective therapeutic agent for COVID 19 when co-administered with ashwagandha as nanoparticles
Article Details
Unique Paper ID: 153852 Publication Volume & Issue: Volume 8, Issue 9 Page(s): 97 - 99
Article Preview & Download

Share This Article

AICTE Sponsored National Conference on Smart Systems and Technologies

Last Date: 25th November 2021

LATEST INNOVATION’S AND FUTURE TRENDS IN MANAGEMENT

Last Date: 7th November 2021

IJIRT.org enables door in research by providing high quality research articles in open access market.

Send us any query related to your research on editor@ijirt.org